OncoMatch

OncoMatch/Clinical Trials/NCT03579875

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Is NCT03579875 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for fanconi anemia.

Phase 2RecruitingMasonic Cancer Center, University of MinnesotaNCT03579875Data as of Jun 2026

Treatment: Total Body Irradiation (TBI) (Plan 1) · Cyclophosphamide (CY) (Plan 1) · Fludarabine (FLU) · Methylprednisolone (MP) · Donor mobilized PBSC infusion · G-CSF · Cyclophosphamide (CY) (Plan 2) · Rituximab · Busulfan · Alemtuzumab · Melphalan · RituximabThis is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

RituximabAlemtuzumabRituximab

Chemotherapy

Cyclophosphamide (CY) (Plan 1)Cyclophosphamide (CY) (Plan 2)BusulfanMelphalan

Other

Total Body Irradiation (TBI) (Plan 1)Fludarabine (FLU)Methylprednisolone (MP)Donor mobilized PBSC infusionG-CSF

Cancer type

Myelodysplastic Syndrome

Demographics

Ages ≤ 65

Lab requirements

Blood counts

hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)

Kidney function

serum creatinine < 1.8 mg/dl

Liver function

Adequate liver function (ALT < 2 x upper limit of normal)

Cardiac function

Adequate cardiac function

Adequate pulmonary, cardiac and liver function; Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin); Hepatic: ALT < 2 x upper limit of normal; Renal: serum creatinine < 1.8 mg/dl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Masonic Cancer Center at University of Minnesota · Minneapolis, Minnesota

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT03579875 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify